Diana Brainard
Chief Executive Officer chez ALLOVIR, INC.
Fortune : 632 891 $ au 31/03/2024
Profil
Diana M.
Brainard is currently the Chief Executive Officer & Director at AlloVir, Inc., an Independent Director at Nektar Therapeutics, an Independent Director at Affinia Therapeutics, Inc., and an Executive Partner at MPM BioImpact, Inc. Previously, she worked at Gilead Sciences, Inc. as the Senior VP-HIV & Emerging Viral Infections from 2015 to 2021.
Dr. Brainard received her undergraduate degree from Brown University in 1992 and her doctorate degree from Tulane University School of Medicine in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALLOVIR INC
0,70% | 19/04/2024 | 802 935 ( 0,70% ) | 606 216 $ | 31/03/2024 |
NEKTAR THERAPEUTICS
0,02% | 19/09/2023 | 28 560 ( 0,02% ) | 26 675 $ | 31/03/2024 |
Postes actifs de Diana Brainard
| Sociétés | Poste | Début |
|---|---|---|
| ALLOVIR, INC. | Chief Executive Officer | 17/05/2021 |
| NEKTAR THERAPEUTICS | Director/Board Member | 11/11/2021 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 08/03/2022 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - |
Anciens postes connus de Diana Brainard
| Sociétés | Poste | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
Formation de Diana Brainard
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
